The firstMIND and frontMIND trials explore the comparison and association of tafasitamab plus lenalidomide and R-CHOP as the first line in DLBCL, based on the treatment strategy concept that targeting both CD19 and CD20 on B tumor cells may limit target evasion in patients with low CD20 expression (Table 1) [40,41]. Here, CD19 is linked to neoplasm.